Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Terns Pharmaceuticals (TERN) Shares Outstanding (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Shares Outstanding readings, the most recent being $112.3 million for Q4 2025.

  • Quarterly Shares Outstanding rose 28.92% to $112.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.3 million through Dec 2025, up 28.92% year-over-year, with the annual reading at $112.3 million for FY2025, 28.92% up from the prior year.
  • Shares Outstanding hit $112.3 million in Q4 2025 for Terns Pharmaceuticals, up from $87.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $112.3 million in Q4 2025 and bottomed at $25.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $58.4 million, with a median of $61.4 million recorded in 2023.
  • The largest annual shift saw Shares Outstanding surged 11499.3% in 2021 before it rose 0.91% in 2022.
  • Terns Pharmaceuticals' Shares Outstanding stood at $25.3 million in 2021, then soared by 112.6% to $53.7 million in 2022, then grew by 20.2% to $64.6 million in 2023, then soared by 34.92% to $87.1 million in 2024, then rose by 28.92% to $112.3 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Shares Outstanding are $112.3 million (Q4 2025), $87.5 million (Q3 2025), and $87.5 million (Q2 2025).